Table I.
Characteristics of 175 patients with chronic myeloid leukaemia at the time of mutation screening.
| BCR-ABL1 mutation | ||||
|---|---|---|---|---|
| Variable | N | Present (n=54) | Absent (n=121) | P-value |
| Sex | <0.001a | |||
| Male | 111 | 22 | 89 | |
| Female | 64 | 32 | 32 | |
| Age, years | 0.320 | |||
| Mean, 43 (range, 3–76) | 169 | 44 (3–71) | 42 (3–76) | |
| Missing | 6 | |||
| Disease phase at diagnosis | 0.253 | |||
| CP | 162 | 48 | 114 | |
| AP | 4 | 1 | 3 | |
| BC | 9 | 5 | 4 | |
| Time between TKI and mutation screen, month | 0.140 | |||
| Mean, 21.5 (range, 0–99) | 166 | 17.3 (0–92) | 23.5 (0–99) | |
| Missing, n | 9 | 4 | 5 | |
| Type of transcription | 0.230 | |||
| P210 | 167 | 50 | 117 | |
| P230 | 8 | 4 | 4 | |
| Choice of TKI generation at diagnosis | 0.790 | |||
| First | 164 | 51 | 113 | |
| Second | 11 | 3 | 8 | |
| Additional chromosome | 0.989 | |||
| Present | 39 | 12 | 27 | |
| Absent | 136 | 42 | 94 | |
a
P<0.05. CP, chronic phase; AP, accelerated phase; BC, blast crisis; m, month; missing, loss of follow-up; P210, M-type b3a2 (e14a2), b2a2 (e13a2); P230, µ-type e19a2; TKI, tyrosine kinase inhibitor; additional chromosome, in addition to the Philadelphia chromosome attached to other abnormal chromosomes.